This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor
Role of RANKL inhibition in osteoporosis
-
Correspondence: Michael McClung mmcclung@orost.com
Arthritis Research & Therapy 2007, 9(Suppl 1):S3 doi:10.1186/ar2167
Accesses
- Last 30 days: 125 accesses
- Last 365 days: 1108 accesses
- All time: 6191 accesses